Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Intra-Cellular Therapies, Inc.    ITCI

INTRA-CELLULAR THERAPIES, INC.

(ITCI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

FDA approves Intra-Cellullar's schizophrenia drug, shares soar 85%

share with twitter share with LinkedIn share with facebook
share via e-mail
12/23/2019 | 08:48am EDT
FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is seen in Silver Spring, Maryland

Intra-Cellular Therapies Inc said on Monday its lead drug to treat schizophrenia in adults has received approval from the U.S. Food and Drug Administration, sending its shares soaring 85%.

The company said it will price the drug, Caplyta, closer to its launch.

Caplyta, which has been approved as a once-daily dose of 42 mg, has shown to regulate three neurotransmitter systems — serotonin, dopamine and glutamate — linked to severe mental illnesses.

Intra-Cellular plans to launch the drug later in the first quarter of 2020 and is in talks with health insurers on the its potential coverage. The company will market Caplyta on its own worldwide, it said.

The approval comes with FDA's harshest warning that the drug is not for the treatment of patients with dementia-related psychosis.

Schizophrenia is a chronic mental disorder that causes distortion in thoughts, hallucinations and feelings of fright and paranoia, affecting about 2.4 million adults in the United States.

An approval will de-risk the market inefficiency driven by investors' concerns regarding the pace at which Caplyta will be adopted post launch as a differentiated neuropsychiatric product in early 2020, Cantor Fitzgerald analyst Charles Duncan said, ahead of the FDA decision.

"We anticipate first couple of quarters to be driven by pharmacy stockpiling with sales revenue reflecting in the third quarter of 2020," added Fitzgerald.

Existing anti-psychotic drugs in the market include Rexulti from Danish drugmaker H. Lundbeck A/S and Japan’s Otsuka Pharmaceutical Co Ltd, Allergan Plc’s Vraylar and Johnson & Johnson's Invega.

In trials, Caplyta did not cause akathisia, a feeling of jitteriness among patients, which is extraordinarily uncomfortable and makes people "jump out of their skin", the company said.

The drug is also being developed by Intra-Cellular for other indications including bipolar depression, depressive disorders and agitation in patients with Alzheimer’s disease.

Shares of the company were trading at $23 before the bell and were set to open at more than one and a half year high.

By Trisha Roy

Stocks mentioned in the article
ChangeLast1st jan.
ALLERGAN PLC -1.03% 175.71 Delayed Quote.-8.09%
INTRA-CELLULAR THERAPIES, INC. 0.35% 14.4 Delayed Quote.-58.03%
OTSUKA CORPORATION 0.98% 4620 End-of-day quote.0.43%
OTSUKA HOLDINGS CO., LTD. -1.49% 4231 End-of-day quote.-0.68%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on INTRA-CELLULAR THERAPIES,
04/03INTRA CELLULAR THERAPIES : Initiates Promotional Activities for CAPLYTA for the ..
AQ
04/02Intra-Cellular Therapies Initiates Promotional Activities for CAPLYTA™ ..
GL
03/24INTRA CELLULAR THERAPIES : Announces Availability of CAPLYTA for Adult Patients ..
AQ
03/23INTRA-CELLULAR THERAPIES, INC. : Other Events, Financial Statements and Exhibits..
AQ
03/23Intra-Cellular Therapies Announces Availability of CAPLYTA™ (lumatepero..
GL
03/02INTRA CELLULAR THERAPIES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CON..
AQ
03/02INTRA-CELLULAR : 4Q Earnings Snapshot
AQ
03/02INTRA-CELLULAR THERAPIES, INC. : Results of Operations and Financial Condition, ..
AQ
03/02Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2019 Financial ..
GL
02/24INTRA CELLULAR THERAPIES : Announces Inducement Grants under Nasdaq Listing Rule..
AQ
More news
Financials (USD)
Sales 2020 25,9 M
EBIT 2020 -235 M
Net income 2020 -232 M
Finance 2020 240 M
Yield 2020 -
P/E ratio 2020 -4,11x
P/E ratio 2021 -5,28x
EV / Sales2020 27,4x
EV / Sales2021 5,45x
Capitalization 949 M
Chart INTRA-CELLULAR THERAPIES, INC.
Duration : Period :
Intra-Cellular Therapies, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INTRA-CELLULAR THERAPIES,
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Average target price 43,78  $
Last Close Price 14,35  $
Spread / Highest target 388%
Spread / Average Target 205%
Spread / Lowest Target 81,2%
EPS Revisions
Managers
NameTitle
Sharon Mates Chairman, President & Chief Executive Officer
Lawrence J. Hineline Chief Financial Officer, Treasurer & SVP-Finance
Robert E. Davis Chief Scientific Officer & Senior Vice President
Andrew Satlin Chief Medical Officer & Executive Vice President
Suresh Durgam Senior Vice President-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
INTRA-CELLULAR THERAPIES, INC.-58.03%1 016
GILEAD SCIENCES20.36%94 124
VERTEX PHARMACEUTICALS8.84%61 693
REGENERON PHARMACEUTICALS31.38%53 154
WUXI APPTEC CO., LTD.0.00%21 017
GENMAB A/S-6.88%13 229